Edwards Lifesciences Corp (NYSE: EW) on Friday, plunged -0.95% from the previous trading day, before settling in for the closing price of $78.8. Within the past 52 weeks, EW’s price has moved between $58.93 and $95.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.36%. The company achieved an average annual earnings per share of 1.70%. With a float of $574.69 million, this company’s outstanding shares have now reached $586.20 million.
Let’s determine the extent of company efficiency that accounts for 15800 employees. In terms of profitability, gross margin is 79.18%, operating margin of 26.75%, and the pretax margin is 29.13%.
Edwards Lifesciences Corp (EW) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Edwards Lifesciences Corp is 2.03%, while institutional ownership is 87.35%. The most recent insider transaction that took place on Jun 16 ’25, was worth 673,268. In this transaction Global President TAVR & Surg of this company sold 8,950 shares at a rate of $75.23, taking the stock ownership to the 206,900 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 8,950 for $75.23, making the entire transaction worth $673,268.
Edwards Lifesciences Corp (EW) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.56% during the next five years compared to -2.36% drop over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Edwards Lifesciences Corp (EW) is currently performing well based on its current performance indicators. A quick ratio of 3.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.27. Likewise, its price to free cash flow for the trailing twelve months is 72.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.50, a number that is poised to hit 0.62 in the next quarter and is forecasted to reach 2.76 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Looking closely at Edwards Lifesciences Corp (NYSE: EW), its last 5-days average volume was 3.13 million, which is a drop from its year-to-date volume of 4.46 million. As of the previous 9 days, the stock’s Stochastic %D was 73.08%.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 93.44%, which indicates a significant increase from 84.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.48 in the past 14 days, which was lower than the 1.68 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $76.31, while its 200-day Moving Average is $72.07. However, in the short run, Edwards Lifesciences Corp’s stock first resistance to watch stands at $78.61. Second resistance stands at $79.16. The third major resistance level sits at $79.94. If the price goes on to break the first support level at $77.27, it is likely to go to the next support level at $76.49. Now, if the price goes above the second support level, the third support stands at $75.94.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
Market capitalization of the company is 45.78 billion based on 586,600K outstanding shares. Right now, sales total 5,440 M and income totals 4,175 M. The company made 1,413 M in profit during its latest quarter, and 358,000 K in sales during its previous quarter.